Eloxx Pharmaceuticals Stock Price

-0.0044 (-3.04%)
Upgrade to Real-Time
Regular Market
Volume 237,719
Bid Price 0.1405
Ask Price 0.1499
News -
Day High 0.152


52 Week Range


Day Low 0.1405
Company Name Stock Ticker Symbol Market Type
Eloxx Pharmaceuticals Inc ELOX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.0044 -3.04% 0.1405 14:32:37
Open Price Low Price High Price Close Price Prev Close
0.1474 0.1405 0.152 0.1449
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
250 237,719 $ 0.1454487 $ 34,576 - 0.1052 - 1.01
Last Trade Time Type Quantity Stock Price Currency
14:24:41 16 $ 0.1476 USD


Draw Mode:

Eloxx Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 12.18M 86.66M 71.57M $ - $ - -0.97 -0.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 23.20%

more financials information »

Eloxx Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ELOX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.130.180.12550.144188894,4980.01058.08%
1 Month0.15880.180.10520.138769335,065-0.0183-11.52%
3 Months0.35750.420.10520.1734692230,231-0.217-60.7%
6 Months0.2810.480.10520.2431549222,684-0.1405-50.0%
1 Year0.711.010.10520.4704895309,184-0.5695-80.21%
3 Years5.078.16140.10521.72423,588-4.93-97.23%
5 Years10.3524.600.10522.81312,369-10.21-98.64%

Eloxx Pharmaceuticals Description

Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis.